Routine annual meeting with no financial disclosures or material developments — no actionable trading signal. Monitor upcoming quarterly filings for pipeline updates and cash runway.
Price Chart
Executive Summary
Dermata Therapeutics held its 2026 Annual Meeting on May 27, 2026. Stockholders approved several proposals including the re-election of three Class II directors, ratification of CBIZ CPAs P.C. as auditor, issuance of shares underlying warrants (Issuance Proposal), repricing of certain warrants, and an amendment to the 2021 Omnibus Equity Incentive Plan increasing authorized shares from 153,586 to 402,214. Approximately 59% of outstanding shares were represented. No financial data, guidance, or material operational updates were disclosed—this is a routine governance filing.
Key Facts
- Approximately 59% (2,374,471 shares) of outstanding common stock was represented at the annual meeting.
- Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing shares reserved for issuance from 153,586 to 402,214.
- The Issuance Proposal (approval of share issuance underlying warrants under a December 2025 SPA) was approved with 315,477 For, 22,696 Against, 967,642 Abstain, and 1,068,656 Broker Non-Votes.
- The Warrant Repricing Proposal (repricing of warrants for up to 120,734 shares) was approved with 439,573 For, 21,203 Against, 845,039 Abstain.
- Three Class II directors (David Hale, Steven Mento, Brittany Bradrick) were elected to serve until the 2029 annual meeting.
- Ratification of CBIZ CPAs P.C. as independent auditor for FY 2026 was approved (2,329,537 For).
- No financial results, guidance, or material corporate developments were reported.
Financial Impact
No financial data reported; plan amendment increases potential equity dilution by adding up to 248,628 shares to the equity pool (from 153,586 to 402,214)
Risk Factors
- Potential dilution from increased share reserve under equity plan (now 402,214 shares total), though small in absolute terms given the company's micro-cap status.
- High percentage of abstentions on Issuance Proposal (967,642) and Warrant Repricing Proposal (845,039) suggests retail/long holder uncertainty about warrant-related dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025441 |
| Exhibit: ex10-1.htm | 0001493152-26-025441 |
| Document: 0001493152-26-025441-index-headers.html | 0001493152-26-025441 |
| Document: 0001493152-26-025441-index.html | 0001493152-26-025441 |
| Document: 0001493152-26-025441.txt | 0001493152-26-025441 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 1, 2026 21w ago | EFFECT | $0.0183 $0.0103 | ▲ +43.72% | ▲ +42.42% | — |
May 27, 2026 21w ago | 8-K | $0.0183 $0.0183 | · 0.00% | ▲ +2.44% | — |
Apr 17, 2026 27w ago | DEFA14A | $0.0183 $0.0183 | · 0.00% | ▼ −4.20% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers